Recruiting Type 1 Diabetes Studies in Aurora
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 week...
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last abo...
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogeno...
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Wheth...
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage...
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-da...
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answer are: * Does it reduce stress on the cells that make insu...
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has ...
About Type 1 Diabetes Clinical Trials in Aurora
Type 1 diabetes is an autoimmune condition where the immune system destroys insulin-producing beta cells in the pancreas. It typically develops in childhood or young adulthood and requires lifelong insulin therapy. Research is exploring artificial pancreas systems, immunotherapy, and beta cell replacement.
There are currently 8 type 1 diabetes clinical trials recruiting participants in Aurora, CO. These studies are seeking a combined 2,130 participants. Research is being sponsored by Eli Lilly and Company, Diamyd Medical AB, Alessandro Doria and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Type 1 Diabetes Clinical Trials in Aurora — FAQ
Are there type 1 diabetes clinical trials in Aurora?
Yes, there are 8 type 1 diabetes clinical trials currently recruiting in Aurora, CO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Aurora?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.
Are clinical trials in Aurora free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.
What type 1 diabetes treatments are being tested?
The 8 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for type 1 diabetes.
Data updated March 2, 2026 from ClinicalTrials.gov